Mexico Biosimilar Market

Mexico Biosimilar Market Overview:

The Mexico biosimilar market size reached USD 417.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,560.8 Million by 2033, exhibiting a growth rate (CAGR) of 14.60% during 2025-2033. The market is driven by the increasing price of biologic drugs, government efforts to contain healthcare expenses, and demand for cost-effective treatments. Moreover, the growing awareness and acceptance by healthcare providers and regulatory enhancements about biosimilars are also increasing the uptake of biosimilars in Mexico.

Mexico Biosimilar Market Trends:

Increasing Adoption of Biosimilars in Oncology Treatments

One of the most important trends propelling the Mexico biosimilar market growth is the increasing use of biosimilars for oncology indications. Cancer therapy, which frequently involves biologic treatments, has been a primary focus for biosimilar development, as most biologics are expensive and not affordable to most of the population. When original biologics' patents expire, biosimilars provide a lower-cost option for patients and healthcare systems alike. In Mexico, where access to costly cancer therapies is low, biosimilars are becoming a critical answer in making high-quality oncology treatments more available. The government has increasingly been promoting the utilization of biosimilars in order to decrease healthcare expenses, which has expedited their approval and market adoption. In addition, the favorable clinical effects of biosimilars, in combination with cost benefits, are encouraging an increasing number of healthcare professionals to look at these options, thus boosting their use in cancer treatment.

Government Support and Regulatory Framework Development

The biosimilar regulatory environment in the country has become much better, which has helped increase the size of the Mexico biosimilar market share. The Mexican government has acted to encourage the development and use of biosimilars by establishing a more favorable regulatory climate. The Federal Commission for Protection against Sanitary Risk (COFEPRIS) has established stringent biosimilar approval guidelines, facilitating easier approval processes for manufacturers while making sure the drugs are tested with high standards of safety and efficacy. Also, government health policies to check rising healthcare expenditures have promoted biosimilar drug utilization as a lower-cost alternative to biologic medications, especially among public sector stakeholders. Mexico's increasing interest in biosimilars follows the general trend of cost control in healthcare systems. As regulatory systems continue to evolve to facilitate faster market introduction of biosimilars, the trend is likely to persist, favoring both patients and healthcare providers by making necessary treatments more accessible.

Rising Awareness and Acceptance of Biosimilars Among Healthcare Professionals

An increase in awareness and acceptance of biosimilars among healthcare professionals in Mexico is another significant trend that is fueling market growth. Previously, physicians and healthcare professionals were somewhat hesitant to transition from originator biologics to biosimilars because they were worried about their safety, effectiveness, and interchangeability. With more clinical information coming to hand and real-world experience of biosimilar performance, healthcare professionals are increasingly confident to prescribe biosimilars. Alongside this, there has been rising education effort, training, and greater industry co-operation, contributing to better appreciation of biosimilars. Mexico's professional associations and healthcare organizations have strongly supported biosimilar use, underscoring benefits to both pocket and access. Such change is increasingly erasing the initial misgivings regarding biosimilars and winning acceptance at an ever-increasing scale of market. As healthcare professionals increasingly adopt biosimilars, the Mexico biosimilar market outlook is poised to continue its path toward expansion.

Mexico Biosimilar Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the regional level for 2025-2033. Our report has categorized the market based on molecule, manufacturing type, and indication.

Molecule Insights:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

The report has provided a detailed breakup and analysis of the market based on the molecule. This includes infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, follitropin alfa, adalimumab, pegfilgrastim, trastuzumab, bevacizumab, and others.

Manufacturing Type Insights:

• In-house Manufacturing
• Contract Manufacturing

The report has provided a detailed breakup and analysis of the market based on the manufacturing type. This includes in-house manufacturing and contract manufacturing.

Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

The report has provided a detailed breakup and analysis of the market based on the indication. This includes auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency, female infertility, and others.

Regional Insights:

• Northern Mexico
• Central Mexico
• Southern Mexico
• Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Mexico, Central Mexico, Southern Mexico and others.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Mexico Biosimilar Market News:

• In July 2024, Zydus Lifesciences was granted approval by Mexico’s COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) to sell Bhava, a bevacizumab biosimilar for multiple cancers.3 Bhava will be offered in 100 mg/4 mL and 400 mg/16 mL dosages. Zydus first introduced this biosimilar in India in 2015 under the name Bryxta, with around 50,000 patients having received the biosimilar since its release.

Mexico Biosimilar Market Report Coverage:

Key Questions Answered in This Report:

• How has the Mexico biosimilar market performed so far and how will it perform in the coming years?
• What is the breakup of the Mexico biosimilar market on the basis of molecule?
• What is the breakup of the Mexico biosimilar market on the basis of manufacturing type?
• What is the breakup of the Mexico biosimilar market on the basis of indication?
• What is the breakup of the Mexico biosimilar market on the basis of region?
• What are the various stages in the value chain of the Mexico biosimilar market? 
• What are the key driving factors and challenges in the Mexico biosimilar market?
• What is the structure of the Mexico biosimilar market and who are the key players?
• What is the degree of competition in the Mexico biosimilar market? 

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Mexico biosimilar market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Mexico biosimilar market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Mexico biosimilar industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.